Natixis Advisors LLC Sells 106,774 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Natixis Advisors LLC significantly reduced its stake in IQVIA Holdings by 67.0%, selling 106,774 shares and leaving them with 52,663 shares valued at approximately $9.29 million.
• IQVIA has received varying analyst ratings, with 17 analysts giving it a "buy" rating, while the consensus target price has been set at $228.62.
• The company reported quarterly earnings of $2.81 EPS, surpassing expectations and showing a revenue increase of 5.3% year-over-year.

Natixis Advisors LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 67.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,663 shares of the medical research company's stock after selling 106,774 shares during the quarter. Natixis Advisors LLC's holdings in IQVIA were worth $9,285,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. American National Bank & Trust acquired a new stake in shares of IQVIA during the first quarter worth $26,000. Golden State Wealth Management LLC raised its position in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA in the 1st quarter worth $33,000. ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. Finally, GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA in the 4th quarter worth $39,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Mizuho set a $225.00 target price on IQVIA and gave the stock an "outperform" rating in a research report on Friday, July 25th. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group raised their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, Barclays raised their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Price Performance

IQVIA stock traded up $1.08 during trading hours on Tuesday, hitting $183.83. 2,522,795 shares of the stock were exchanged, compared to its average volume of 2,384,021. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $31.25 billion, a P/E ratio of 26.60, a P/E/G ratio of 2.01 and a beta of 1.30. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The business's 50-day moving average is $163.03 and its two-hundred day moving average is $169.60.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the firm earned $2.64 earnings per share. IQVIA's revenue was up 5.3% compared to the same quarter last year. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.